RSNA 2023 showcased Koning Health’s groundbreaking Koning Vera Breast CT, revolutionizing breast cancer detection with its unparalleled 3D imaging and biopsy capabilities. The event underscored the urgency for early cancer detection, emphasizing KBCT’s ability to identify minute lesions and calcifications. Partnering with Swissray, Koning attracted a diverse audience, including clinicians and researchers, solidifying its technological superiority over competitors. RSNA validated KBCT’s pivotal role, cementing Koning Health’s status as an industry leader committed to providing advanced diagnostic solutions worldwide.
Koning Health, a trailblazer in pioneering breast imaging solutions, proudly announced its participation in the highly acclaimed Radiological Society of North America (RSNA) 2023 Annual Meeting. Renowned for its comprehensive educational courses, scientific sessions, and groundbreaking technical exhibits, the event provided an unparalleled platform for Koning to unveil its revolutionary creation, the Koning Vera Breast CT.
The RSNA 2023 gathering, attended by a multitude of industry professionals, spotlighted the most recent advancements in radiology, presenting a repertoire of over 400 educational and scientific sessions. Capitalizing on this opportunity, Koning Health showcased the FDA PMA approved Koning Vera Breast CT (KBCT), marking a new epoch in commercially available breast CT technology. With an impressive scanning time of merely 7 seconds per breast and multifaceted capabilities enabling highly detailed 3D assessment of breast tissue along with 3D guided biopsy, the Vera system has redefined the benchmarks in breast cancer imaging.
Early detection is pivotal in effectively treating breast cancer. Conventional mammography, which fails to detect around 30% of cancers, has posed a significant challenge in achieving early diagnoses. The KBCT bridges this gap by introducing NO-COMPRESSION, TRUE 3D Breast CT technology, substantially enhancing the detection of breast cancer. Its proficiency in identifying cancers as early as stage 0 and stage 1, detecting lesions as minute as 2mm, and pinpointing calcifications as small as 200 microns signifies a momentous stride forward in early cancer detection.
Koning had the privilege of presenting its groundbreaking device at the Swissray booth during the recent RSNA event. Notably, Swissray has recently joined hands with Koning as one of its distributor partners. The booth captivated a significant influx of visitors, comprising clinicians, researchers, and healthcare professionals, all keen on unraveling the transformative potential of the KBCT. The device’s unparalleled sensitivity, coupled with its versatility to replace multiple imaging applications such as biopsy, contrast enhancement, and serve as an alternative to breast MRI imaging, generated considerable interest. Evidently, Koning maintains a prominent technological and regulatory edge over its competitors, who also had a presence at RSNA.
RSNA served as a watershed moment for Koning Health, reaffirming its status as an industry trailblazer in breast imaging and underscoring the necessity of breast CT as an alternative imaging option for patients. The company’s collaboration with Swissray at this prestigious event not only underscored its unwavering commitment to advancing healthcare but also highlighted its dedication to furnishing superior diagnostic solutions for millions of women across the globe.
RSNA 2023 positioned Koning Health at the forefront of breast imaging innovation with the unveiling of the Koning Vera Breast CT. This milestone emphasized the critical importance of early cancer detection, spotlighting KBCT’s ability to detect minute anomalies. The collaboration with Swissray served as a testament to KBCT’s market superiority, attracting a diverse audience and solidifying Koning’s technological edge. RSNA validated KBCT’s significance, cementing Koning Health’s status as an industry leader dedicated to delivering advanced diagnostic solutions globally.
